Condition: Differentiated Thyroid Cancer · Anaplastic Thyroid Cancer · Sponsor: Grupo Espanol de Tumores Neuroendocrinos
SETHY is a prospective, multicohort, phase II, single-arm, non-randomized, non-blinded, investigator-initiated study of sacituzumab govitecan in patients with advanced or metastatic radioactive-iodine refractory differentiated thyroid carcinoma (DTC) or anaplastic thyroid carcinoma (ATC). The main hypothesis is that treatment with sacituzumab govitecan, a anti-Trophoblast cell surface antigen 2 (TROP-2), could be an effective treatment option for patients with either differentiated and anaplastic thyroid neoplasms because TROP-2 is highly expressed at the membrane of DTC and ATC.
This description comes directly from the study's public registry record.
A responsible person Designated by the Sponsor · +34 93 434 44 12 · investigacion@mfar.net
Always discuss trial participation with your own doctor first.
| Hospital Universitari Vall d'Hebron | Barcelona, Spain | Recruiting |
| Complexo Hospitalario Universitario de Ferrol | Ferrol, Spain | Not Yet Recruiting |
| Institut Catala d´Oncologia (ICO) -Hospitalet | Hospitalet de Llobregat (Barcelona), Spain | Recruiting |
| Hospital Clínico San Carlos | Madrid, Spain | Recruiting |
| Hospital Universitario la Paz | Madrid, Spain | Recruiting |
| Hospital Universitario Ramón y Cajal | Madrid, Spain | Not Yet Recruiting |
| MD Anderson Cancer Center Madrid | Madrid, Spain | Recruiting |
| Hospital General Universitario Morales Meseguer | Murcia, Spain | Recruiting |
| Hospital Universitario Central de Asturias | Oviedo, Spain | Recruiting |
| H.U. Marqués de Valdecilla | Santander, Spain | Recruiting |
| Hospital Universitario Miguel Servet | Zaragoza, Spain | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06235216